The study by [@bib9] is a highly interesting work, revealing the potential of PRAME (preferentially expressed antigen of melanoma) for diagnostic discrimination of human type II germ cell cancers. Moreover, the presented data is incorporated into a model placing PRAME into a decisive position for the cell fate choice with regard to pluripotency or differentiation in primordial germ cells and seminomas.

Cancer/testis antigens (CTAs) have a specific expression profile as they can only be detected in human malignancies but not in healthy human tissues, with the exception of the testis. Based on this profile, CTAs are assumed to be involved in regulation of gene expression or cell cycle in tumour cells. In 1997 the CTA termed PRAME was first described ([@bib7]). Because of its expression pattern, numerous studies focused on the potential of PRAME as a biomarker for monitoring minimal residual disease, for diagnosis of malignant diseases and even as candidate for immunotherapy ([@bib4], [@bib5]). Although expression of PRAME in healthy human testicular tissues has been shown ([@bib7]), [@bib9] are now the first to provide information on the expression profile in human primordial germ cells and in testicular germ cell cancers. Primordial germ cells are the precursors of the germline stem cells that provide the basis for lifelong spermatogenesis. Importance of the regulatory mechanisms guiding this differentiation is highlighted by the fact that developmentally arrested primordial germ cells are considered to be the origin of type II germ cell cancers. More specifically, these defect primordial germ cells are thought to transform into a precursor lesion, namely germ cell neoplasia *in situ* (GCNIS). Later in life, these cells give rise to seminomas or embryonal carcinomas, the latter of which can differentiate into teratomas, yolk-sac tumours and chorioncarcinomas ([@bib12]). Although seminomas and embryonal carcinomas share expression of pluripotency markers, these testicular germ cell cancers show distinct expression patterns of SOX2 and SOX17, which are restricted to embryonal carcinomas and seminomas, respectively ([@bib2]).

Aiming to identify other key players accompanying the transition from a seminoma to an embryonal carcinoma, [@bib11] recently established xenografting of seminoma cells into the flank of mouse hosts. This microenvironment resulted in cellular transition into an embryonal carcinoma-like status. Intriguingly, the transition process was accompanied by an induction of *SOX2* but down-regulation of *SOX17* and interestingly, also *PRAME*.

This study follows up on PRAME expression characteristics. In particular, [@bib9] performed a meta-analysis of RNA-sequencing data from rarely available human primordial germ cells ([@bib6], [@bib8], [@bib14]) as well as analyses of testicular germ cell tissues and cell lines. Employing this elegant approach, PRAME expression was revealed in human primordial germ cells, normal adult human testes in GCNIS seminomas, but not in embryonal carcinomas. This distinct expression profile on the one hand, again, supports the germ cell origin of seminomas, but also highlights the possibility to use PRAME in combination with the established markers SOX2 and SOX17 for diagnostic discrimination of seminomas and embryonal carcinomas ([@bib9]).

This study also evaluated the regulatory mechanisms influencing PRAME expression and action, respectively. Nettersheim *et al* showed the expression of PRAME to be regulated by DNA methylation in type II germ cell cancers, which is in line with previous data from myeloid leukemia cells ([@bib13]). Also, Nettersheim *et al* addressed the hypothesis that knock-down of PRAME renders TCam-2 cells sensitive towards retinoic acid-induced differentiation. Although this effect has been demonstrated for human melanoma cells ([@bib3]), knock-down of PRAME in seminoma cells did not result in a sensitisation of TCam-2 cells towards a retinoic acid-induced differentiation process.

Nonetheless, PRAME knock-down in TCam-2 cells did result in down-regulation of pluripotency regulators and an up-regulation of genes including factors associated with endodermal, mesodermal as well as germ cell differentiation. Importantly, expression of SOX17 was not altered, indicating an upstream function of this transcription factor.

Although the exact mechanism of PRAME action remains to be resolved, Nettersheim *et al* propose a model for PRAME function in seminoma cells that is based on recent insights gained from mouse studies demonstrating that interaction of Sox2 and Oct3/4 leads to binding to canonical motifs associated with pluripotency, whereas interaction of Sox17 and Oct3/4 leads to binding to compressed motifs associated with differentiation ([@bib1], [@bib15]). In the human, however, SOX17 expression in primordial germ cells and seminoma cells does not lead to spontaneous differentiation. Rather, SOX17 has recently been described as master regulator at the time of germ cell specification, leading to transactivation of primordial germ cell markers ([@bib6], [@bib8], [@bib14]). Also, the ability of SOX17 to bind canonical motifs suggests that in seminomas, SOX2 may be replaced by SOX17 in the pluripotency cluster. Based on these recent findings and their own data, Nettersheim *et al* therefore propose that the presence of PRAME leads to binding of SOX17/OCT4 dimers to canonical motifs, leading to expression of pluripotency factors and manifestation of the primordial germ cell or seminoma cell identity. In the absence of PRAME, however, binding of SOX17/OCT4 dimers changes toward the compressed motifs, leading to expression of germ and somatic cell differentiation markers ([@bib9]).

In three very recent publications ([@bib11], [@bib9], [@bib10]) this group has unravelled molecular changes that accompany the transition from seminoma to embryonal carcinoma. They also propose intriguing models for the respective cellular mechanisms. The model concerning cellular mechanisms of PRAME presented in this study will need to be substantiated by further functional studies.
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